JAZZ Jazz Pharmaceuticals Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Jazz Pharmaceuticals plc (JAZZ)

Quarterly EPS dynamics reveal hidden financial imbalances, with the parameter reaching -283.90. Jazz Pharmaceuticals (JAZZ) is expanding its innovation pipeline through partnerships with biotech startups in oncology and somnology. The company is minimizing its carbon footprint by adhering to strict governance ethics. High operating margins and excess liquidity ensure stable funding for new medical developments.

Jazz Pharmaceuticals plc (JAZZ) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Jazz Pharmaceuticals

- share price and consensus valuation forecast:
Fundamental company analysis:jazzpharma.com, JAZZ
Manufactured product of Jazz Pharmaceuticals Corp

This indicator measures the dynamics of net earnings per share by comparing the current quarter with the same period last year. The metric allows for the separation of real business efficiency from market optimism. By analyzing the quarterly shift in earnings per share, an investor assesses the sustainability of growth rates. For Jazz Pharmaceuticals (JAZZ), this is critical during supply chain disruptions from Asia. Geopolitical risks directly impact the final yield.

Analysis of competing companies

CYTK (Cytokinetics Inc.) - Year-over-year net earnings per share growth for the last 12 months|PTC Bio (PTCT) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Scholar Rock|CNTA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Dyne Therapeutics (DYN)|EWTX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Rapport Pharma RAPP|Alumis Pharma - Year-over-year earnings per share growth for the last twelve months|ZVRA - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata